MQS Management LLC Takes $390,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
MQS Management LLC Takes $390,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
MQS Management LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 5,052 shares of the biotechnology company's stock, valued at approximately $390,000.
根據MQS Management LLC最近提交給美國證券交易委員會的13F文件,該公司在第一季度購買了BioMarin Pharmtics Inc.(BMRN-GET Rating)的新股份。該基金購買了這家生物技術公司的5,052股股票,價值約39萬美元。
A number of other institutional investors also recently modified their holdings of BMRN. Allspring Global Investments Holdings LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $1,811,000. Yousif Capital Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $228,000. Dupont Capital Management Corp bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $113,000. IndexIQ Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 26.9% in the fourth quarter. IndexIQ Advisors LLC now owns 4,000 shares of the biotechnology company's stock valued at $353,000 after purchasing an additional 849 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in shares of BioMarin Pharmaceutical by 40.1% in the fourth quarter. Toronto Dominion Bank now owns 36,158 shares of the biotechnology company's stock valued at $3,195,000 after purchasing an additional 10,344 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.
其他一些機構投資者最近也調整了對BMRN的持股。AllSpring Global Investments Holdings LLC在第四季度購買了BioMarin Pharmtics的新股,價值約1,811,000美元。Yousif Capital Management LLC在第四季度購買了BioMarin Pharmtics的新股,價值約22.8萬美元。杜邦資本管理公司(DuPont Capital Management Corp)在第四季度購買了BioMarin Pharmtics的新股,價值約11.3萬美元。IndexIQ Advisors LLC在第四季度增持了BioMarin製藥公司的股票26.9%。IndexIQ Advisors LLC現在持有這家生物技術公司4000股股票,價值35.3萬美元,上個季度又購買了849股。最後,多倫多道明銀行在第四季度增持了BioMarin製藥公司的股票40.1%。多倫多道明銀行(Toronto Dominion Bank)現在擁有這家生物技術公司36,158股股票,價值319.5萬美元,上個季度又購買了10,344股。95.45%的股票目前由機構投資者持有。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several analysts recently issued reports on BMRN shares. Jefferies Financial Group reiterated a "buy" rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, May 4th. Cantor Fitzgerald started coverage on BioMarin Pharmaceutical in a report on Tuesday, July 12th. They set an "overweight" rating and a $110.00 target price on the stock. Barclays upped their target price on BioMarin Pharmaceutical from $112.00 to $125.00 and gave the stock an "overweight" rating in a report on Thursday, August 4th. Wedbush reiterated a "hold" rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, June 24th. Finally, Credit Suisse Group upped their target price on BioMarin Pharmaceutical to $111.00 in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $110.93.
幾位分析師最近發佈了關於BMRN股票的報告。傑富瑞金融集團在5月4日(週三)的一份報告中重申了對BioMarin製藥公司的評級,併為其股票設定了100.00美元的目標價。坎託·菲茨傑拉德在7月12日星期二的一份報告中開始對BioMarin製藥公司進行報道。他們為該股設定了“增持”評級和110.00美元的目標價。巴克萊在8月4日週四的一份報告中將BioMarin Pharmtics的目標價從112.00美元上調至125.00美元,並給予該股“增持”評級。韋德布什在6月24日星期五的一份報告中重申了持有的評級,併為BioMarin製藥公司的股票設定了70.00美元的目標價。最後,瑞士信貸集團在週二的一份報告中將BioMarin Pharmtics的目標價上調至111.00美元。三名投資分析師對該股的評級為持有,13名分析師對該公司股票的評級為買入。根據MarketBeat的數據,BioMarin Pharmtics的共識評級為“中等買入”,平均目標價為110.93美元.
Insider Activity
內幕活動
BioMarin Pharmaceutical Price Performance
BioMarin藥品價格表現
Shares of NASDAQ BMRN opened at $95.07 on Friday. BioMarin Pharmaceutical Inc. has a twelve month low of $70.73 and a twelve month high of $97.76. The business's 50 day moving average price is $83.95 and its two-hundred day moving average price is $82.44. The company has a quick ratio of 3.69, a current ratio of 5.42 and a debt-to-equity ratio of 0.24. The company has a market cap of $17.63 billion, a PE ratio of 365.67, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.
上週五,新浪納斯達克的股價開盤報95.07美元。BioMarin製藥公司的股價為70.73美元的12個月低點和97.76美元的12個月高位。該業務的50日移動均線價格為83.95美元,200日移動均線價格為82.44美元。該公司的速動比率為3.69,流動比率為5.42,債務權益比率為0.24。該公司市值為176.3億美元,市盈率為365.67,市盈率為2.08,貝塔係數為0.33.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.78% and a net margin of 2.83%. During the same period in the prior year, the business earned $0.23 EPS. On average, analysts predict that BioMarin Pharmaceutical Inc. will post 0.92 EPS for the current year.
生物馬林製藥公司(納斯達克代碼:BMRN-GET Rating)最近一次公佈財報是在8月3日星期三。這家生物技術公司公佈本季度每股收益為0.15美元,比普遍預期的0.11美元高出0.04美元。BioMarin製藥公司的股本回報率為1.78%,淨利潤率為2.83%。去年同期,該業務的每股收益為0.23美元。分析師平均預測,BioMarin製藥公司本年度每股收益將為0.92%。
About BioMarin Pharmaceutical
關於BioMarin製藥公司
(Get Rating)
(獲取評級)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
BioMarin製藥公司為患有嚴重和危及生命的罕見疾病和醫療條件的人開發和銷售治療方法。它的商業產品包括Vimizim,一種治療粘多糖病IVA型溶酶體儲存障礙的酶替代療法;Naglazyme,一種用於MPS VI患者的N-乙酰半乳糖胺4-硫酸酯酶的重組形式;以及Kuvan,一種專利的6R-BH4的合成口服形式,用於治療一種遺傳性代謝性疾病苯丙酮尿症(PKU)患者。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- 免費獲取StockNews.com關於BioMarin製藥公司(BMRN)的研究報告
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
- 霍尼韋爾看好穩定和多元化的股票
- 為什麼要投資高收益股利股票?
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE:DIS)的股票剛剛給了投資者一個巨大的信號
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating).
想看看還有哪些對衝基金持有BMRN嗎?訪問HoldingsChannel.com獲取BioMarin製藥公司(納斯達克代碼:BMRN-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《BioMarin藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioMarin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。